Serious Mental Illness Treatment Acceleration Act

Constitutional concerns with the original

1. Article I funding: the Order directs at least $50 million from existing ARPA-H funds; any new multiyear program needs identified lawful appropriation authority and spending within available funds.
2. Article II and agency authority: FDA voucher, investigational-access, Schedule I handling, and scheduling actions must fit existing statutes or receive express congressional authorization; the Order itself does not amend those laws.
3. Due process and privacy: patient data sharing and licensing decisions need procedures and protections under the laws that apply to each agency and participant.
4. Federalism: the Order seeks partnerships with states; a congressional grant program should keep state participation voluntary and its conditions clear.

Solution text

Operative provisions

Source basis and limits

Basis: Checked against the full published text of Executive Order 14401, Federal Register document 2026-07907, published April 22, 2026, sections 1 through 6. The Order directs at least $50 million from existing funds and calls for FDA, DEA, HHS, and VA coordination; the five-year ceiling and safeguards here are new VFA proposals. Additional evidence: FDA Right to Try eligibility and sponsor discretion, https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try ; primary ibogaine cardiac-safety observations, https://pmc.ncbi.nlm.nih.gov/articles/PMC9292417/ .

Check before relying on this: Current FDA voucher authority and eligibility, Right to Try requirements and product availability, Schedule I licensing or waiver authority, lawful ARPA-H appropriation availability, applicable privacy and review procedures, and clinical safety or efficacy require separate verification before legislation or patient use. Any particular psychiatric diagnosis, product, sponsor, and clinical protocol must separately meet eligibility and safety requirements; this proposal gives no patient-specific access or treatment recommendation.

Bipartisan rationale

The proposal combines interest in research and treatment access with patient safety, clear spending authority, voluntary state participation, privacy protections, audits, and a sunset. Those design choices offer concrete questions for lawmakers with different priorities; they do not establish party support or a predicted vote.

Constitutional citations

• → Article I, Section 8, Clause 1
• → Article I, Section 9, Clause 7
• → Article II, Section 3
• → Fifth Amendment
• → Tenth Amendment

Article I, Section 8, Clause 1 Article I, Section 9, Clause 7 Article II, Section 3 Amendment V Amendment X

Possible legislative path

Congressional health and judiciary committees would need to examine agency authority, funding, patient safeguards, and state participation against official evidence before any floor vote. This describes a deliberation path, not a forecast of support.